Merck & Co Inc (MRK):企業の財務・戦略的SWOT分析

◆英語タイトル:Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH6319FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Merck & Co Inc (MRK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Merck & Co Inc (Merck) is a biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products like vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc Key Recent Developments

Apr 01,2021: Merck Completes Acquisition of Pandion Therapeutics
Mar 30,2021: Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 29,2021: Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Mar 24,2021: Merck appoints Caroline Litchfield Chief Financial Officer
Mar 17,2021: M2GEN announces new collaboration with Merck to advance cancer therapies

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Merck & Co Inc – Key Facts
Merck & Co Inc – Key Employees
Merck & Co Inc – Key Employee Biographies
Merck & Co Inc – Major Products and Services
Merck & Co Inc – History
Merck & Co Inc – Company Statement
Merck & Co Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate
Joint Venture
Section 2 – Company Analysis
Company Overview
Merck & Co Inc – Business Description
Business Segment: Animal Health
Overview
Performance
Business Segment: Others
Overview
Performance
Business Segment: Pharmaceutical
Overview
Performance
Geographical Segment: Asia Pacific (other than Japan and China)
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe, Middle East and Africa
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Merck & Co Inc – Corporate Strategy
Merck & Co Inc – SWOT Analysis
SWOT Analysis – Overview
Merck & Co Inc – Strengths
Merck & Co Inc – Weaknesses
Merck & Co Inc – Opportunities
Merck & Co Inc – Threats
Merck & Co Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences, Oil & Gas Financial Deals and Alliances
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merck & Co Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 29, 2021: Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Mar 24, 2021: Merck appoints Caroline Litchfield Chief Financial Officer
Mar 17, 2021: M2GEN announces new collaboration with Merck to advance cancer therapies
Mar 17, 2021: Mike Nally to leave Merck; Frank Clyburn to lead all Merck human health
Mar 15, 2021: Gilead and Merck announce agreement to jointly develop and commercialize long-acting, Investigational treatment combinations of Lenacapavir and Islatravir in HIV
Mar 03, 2021: Merck to Present at the Barclays Global Healthcare Conference
Mar 03, 2021: GPHL and Merck build strategic partnership on business innovation and development in GBA
Mar 02, 2021: Merck announces fifth round of global grants to tackle maternal mortality and promote health equity worldwide
Mar 02, 2021: Biden’s latest announcement about invoking DPA
Feb 09, 2021: Merck mourns Hans Joachim Langmann
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Merck & Co Inc, Key Facts
Merck & Co Inc, Key Employees
Merck & Co Inc, Key Employee Biographies
Merck & Co Inc, Major Products and Services
Merck & Co Inc, History
Merck & Co Inc, Subsidiaries
Merck & Co Inc, Affiliate
Merck & Co Inc, Joint Venture
Merck & Co Inc, Key Competitors
Merck & Co Inc, Ratios based on current share price
Merck & Co Inc, Annual Ratios
Merck & Co Inc, Annual Ratios (Cont...1)
Merck & Co Inc, Annual Ratios (Cont...2)
Merck & Co Inc, Interim Ratios
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merck & Co Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Merck & Co Inc (MRK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Timken Company:企業の戦略・SWOT・財務分析
    The Timken Company - Strategy, SWOT and Corporate Finance Report Summary The Timken Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • KOSE Corp:企業の戦略・SWOT・財務情報
    KOSE Corp - Strategy, SWOT and Corporate Finance Report Summary KOSE Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Cook Medical Inc:企業の戦略的SWOT分析
    Cook Medical Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Valero Energy Corp (VLO):石油・ガス:M&Aディール及び事業提携情報
    Summary Valero Energy Corp (Valero) is a downstream company that manufactures and markets transportation fuels and petrochemical products. The company’s assets include petroleum refineries, ethanol plants and renewable diesel production from a joint venture. Its refineries produce gasoline, diesel, …
  • Exelixis Inc (EXEL)-製薬・医療分野:企業M&A・提携分析
    Summary Exelixis Inc (Exelixis) is a biopharmaceutical company focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (c …
  • Team Health Holdings Inc-製薬・医療分野:企業M&A・提携分析
    Summary Team Health Holdings Inc (TeamHealth) is a healthcare organization that offers patient care services. The organization’s practice areas include emergency medicine, anesthesiology, hospital medicine, hospital medicine subspecialties, ambulatory care, post-acute care and behavioral health serv …
  • Lifetech Scientific (Shenzhen) Co Ltd:企業の製品パイプライン分析2018
    Summary Lifetech Scientific (Shenzhen) Co Ltd (Lifetech Shenzhen), a subsidiary of Lifetech Scientific Corp, is a medical device company that offers minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases. The company provides products such as dilator, o …
  • ON Semiconductor Corp (ON):企業の財務・戦略的SWOT分析
    ON Semiconductor Corp (ON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Thermo Fisher Scientific Inc.:企業のM&A・事業提携・投資動向
    Thermo Fisher Scientific Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Thermo Fisher Scientific Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Galectin Therapeutics Inc (GALT):企業の財務・戦略的SWOT分析
    Summary Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company provides products such as GR-MD-02, GM-CT-01, and others. Its GR-MD-02 is a drug c …
  • Softchoice Corporation:企業の戦略・SWOT・財務情報
    Softchoice Corporation - Strategy, SWOT and Corporate Finance Report Summary Softchoice Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Tetragenetics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tetragenetics Inc (Tetragenetics) is a biotechnology company that discovers and develops therapeutics for autoimmune disease and pain. The company develops antibodies for autoimmune disorders, pains and other. Its autoimmune disorders include Type 1 Diabetes Mellitus, rheumatoid arthritis, m …
  • Graham Holdings Company (GHC):企業の財務・戦略的SWOT分析
    Graham Holdings Company (GHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Endocyte Inc (ECYT):企業の財務・戦略的SWOT分析
    Summary Endocyte Inc (Endocyte) is a biopharmaceutical company that develops targeted therapies for the treatment of cancer and inflammatory diseases. The company’s pipeline products include Lu-PSMA-617 and Ac-PSMA-617 for radiologand therapy, and FITC CAR-T. Endocyte's proprietary small molecule dr …
  • Punch Taverns Plc:企業のM&A・事業提携・投資動向
    Punch Taverns Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Punch Taverns Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Idogen AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Idogen AB (Idogen) is a biotechnology company that develops tolerogenic vaccines which reprogram the immune system of paitents. The company provides product portfolio such as antibodies for autoimmune diseases, organ rejection after transplantation and several other disease conditions. It de …
  • PolyOne Corp (POL):企業の財務・戦略的SWOT分析
    PolyOne Corp (POL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bayer AG (BAYN):製薬・医療:M&Aディール及び事業提携情報
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. The company's pr …
  • Fujikura Ltd.:企業の戦略・SWOT・財務情報
    Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • HDR Inc:企業の戦略的SWOT分析
    HDR Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆